Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Patte, Catherine; Aupérin, Anne; Gerrard, Mary; Michon, Jean; Pinkerton, Ross; Sposto, Richard; Weston, Claire; Raphaël, Martine; L. Perkins, Sherrie; McCarthy, Keith; S. Cairo, Mitchell

doi:10.1182/blood-2006-07-036673

Public

Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Published in Blood • Nov 28, 2006

Authors:

Catherine Patte

Anne Aupérin

Mary Gerrard

Abstract

A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as "non-resected" stage II/I and CNS-negative advanced-stage IIV/IV (70% of cases). We performed...

Subject

Cyclophosphamide

Vincristine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!